Seller record · Telehealth service

MultiMedRx

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 3 of 8 criteria. S3, pharmacy identification: No filling facility is identified. The home page says the company is itself a licensed pharmacy that compounds in-house, but no page gives a pharmacy license or location, and the terms describe medication compounded and administered by a physician at the clinic. 2 more criteria also fail; see the table below.

At a glance

MultiMedRxTelehealth service

5/8criteria passed

Price: Compounded semaglutide $139 for the first month as an introductory offer, then regularly $199; tirzepatide $179, then regularly $299
Sells: compounded semaglutide, compounded tirzepatide, GLP-1/GIP microdosing, and 3 more
FDA letters: None on file

Visit MultiMedRx See all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A California telehealth service selling compounded semaglutide and tirzepatide programs, which it says it compounds in-house, after a short health questionnaire and a licensed provider's review, with microdosing blends, metformin and hormone therapy also offered.

Operating entity MultiMedRx LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	MultiMedRx's website; MultiMedRx's our providers page on its company storefront
S2	Prescription gating	PASS	MultiMedRx's website
S3	Pharmacy identification	FAIL	MultiMedRx's website; MultiMedRx's terms and conditions on its company storefront
S4	Compounding disclosure	FAIL	MultiMedRx's website; MultiMedRx's about page on its company storefront
S5	Analytical documentation	FAIL	MultiMedRx's website; MultiMedRx's FAQ on its company storefront; MultiMedRx's legal compliance page on its company storefront
S6	Business address	PASS	MultiMedRx's contact page on its company storefront; MultiMedRx's website
S7	Price disclosure	PASS	MultiMedRx's website; MultiMedRx's terms and conditions on its company storefront
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed healthcare provider reviews each evaluation and prescribes only when treatment is medically appropriate, and the providers page names a physician and a physician assistant.Source: MultiMedRx's website; MultiMedRx's our providers page on its company storefront.

S2PASSThe steps list a three-minute health history evaluation first, a licensed provider's review second and medication only once prescribed, and the pricing applies only to patients a provider approves.Source: MultiMedRx's website.

S3FAILNo filling facility is identified. The home page says the company is itself a licensed pharmacy that compounds in-house, but no page gives a pharmacy license or location, and the terms describe medication compounded and administered by a physician at the clinic.Source: MultiMedRx's website; MultiMedRx's terms and conditions on its company storefront.

S4FAILNo page states that compounded products are not FDA-approved. The compounded programs are sold as having the same active ingredient as Ozempic, Wegovy, Mounjaro and Zepbound, and the about page says the company uses only FDA-approved medications and ingredients.Source: MultiMedRx's website; MultiMedRx's about page on its company storefront.

S5FAILNo certificate of analysis or lot document is published on the program page, the answers, the legal compliance page or the terms.Source: MultiMedRx's website; MultiMedRx's FAQ on its company storefront; MultiMedRx's legal compliance page on its company storefront.

S6PASSMultiMedRx LLC's main office at 1000 Quail St. #260, Newport Beach, CA 92663, printed in the footer and on the contact page, which also lists a telehealth location in Reno, Nevada and a walk-in clinic in Whittier, California.Source: MultiMedRx's contact page on its company storefront; MultiMedRx's website.

S7PASSThe semaglutide program costs $139 for the first month as an introductory offer, regularly $199, and the tirzepatide program $179, regularly $299, each with the provider evaluation, four weeks of medication and shipping, and the offer requires a prepaid total. The terms instead set a monthly patient care fee of $99 to $299 with a $150 medication credit, and clinic-administered semaglutide from $99 and tirzepatide from $139.Source: MultiMedRx's website; MultiMedRx's terms and conditions on its company storefront.

S8PASSNo FDA warning letter names MultiMedRx or MultiMedRx LLC, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, GLP-1/GIP microdosing, metformin, testosterone, hormone replacement therapy.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide

Visit MultiMedRx

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.